2026 MFDS Pharmaceutical Licensing Guideline Update

The Ministry of Food and Drug Safety (MFDS) released a comprehensive guideline revision in Q1 2026 with broad implications for new drug development and market entry procedures. This article summarizes the changes that pharmaceutical regulatory professionals should review first.

Key Changes

1. Digital standardization of IND submission materials

Submission of clinical trial protocols, previously a mix of PDF and paper, is now unified under eCTD 4.0. Mandatory enforcement begins July 2026; ongoing trials transition at their next amendment.

2. Streamlined non-clinical data requirements for biologics

Toxicology testing previously required in three or more animal species shifts to risk-based species selection. Scientific justification for chosen species must be included in the IND.

3. New “K-Breakthrough” accelerated approval track

Therapies for rare and serious diseases can now receive conditional approval based on Phase 2 data alone, paired with mandatory Phase 4 post-market commitments.

Practical Implications

• eCTD transition window: validate internal systems before July mandate
• RA staffing: secure team members fluent in eCTD 4.0 operations
• Trial design: strengthen documentation of non-clinical species rationale

MEDISOL’s Advisory Support

MEDISOL provides consulting for eCTD 4.0 system migration and accelerated approval track applications. Contact us for advisory and we will match you with an appropriate specialist from our network.

This article is for general information only and does not substitute for legal or regulatory advice on specific matters.